Pfizer has reported positive topline outcomes from the multicentre, open-label Phase III BASIS trial of Hympavzi.

Viatris’ presbyopia drug MR-141 (phentolamine ophthalmic solution 0.75%) has met the primary endpoint and all secondary ...

The multiple sclerosis (MS) disease-modifying therapy (DMT) market across the seven major markets (7MM: the US, France, ...

Viking Therapeutics has begun the VANQUISH Phase III clinical programme of VK2735, intended for the potential treatment of ...

Kashiv has reported positive topline outcomes from the confirmatory trial of the proposed biosimilar to Novartis’ Xolair, ADL ...

Bavarian Nordic has initiated two Phase III clinical trials of its mpox vaccine, Jynneos, in pregnant and breastfeeding women ...

The nontuberculous mycobacteria (NTM) market across the seven major markets (7MM) and 5EU (US, France, Germany, Italy, Spain, ...

Bio-Thera Solutions has commenced dosing in the randomised Phase III trial of the antibody-drug conjugate (ADC) BAT8006.

The US Food and Drug Administration (FDA) has approved Gilead Science’s Yeztugo for the prevention of human immunodeficiency ...

Experts at HLTH Europe discussed how to ensure patients have trust in the EHDS to ensure a successful roll-out.

āshibio has commenced subject dosing in the Phase Ib trial, ANDECA-HO, assessing the humanised antibody, andecaliximab, in ...

Leading politicians, medical experts, and campaigners gathered at the Cannabis Europa 2025 conference in London to discuss ...